HK1053058A1 - 普拉克索用於治療成癮性疾病的用途 - Google Patents

普拉克索用於治療成癮性疾病的用途

Info

Publication number
HK1053058A1
HK1053058A1 HK03105334.1A HK03105334A HK1053058A1 HK 1053058 A1 HK1053058 A1 HK 1053058A1 HK 03105334 A HK03105334 A HK 03105334A HK 1053058 A1 HK1053058 A1 HK 1053058A1
Authority
HK
Hong Kong
Prior art keywords
pramipexole
treatment
addictive disorders
addictive
disorders
Prior art date
Application number
HK03105334.1A
Other languages
English (en)
Inventor
R‧C‧馬歇爾
E‧H‧F‧翁
P‧F‧馮沃伊格特蘭德
Original Assignee
法瑪西雅厄普約翰美國公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22676121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1053058(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 法瑪西雅厄普約翰美國公司 filed Critical 法瑪西雅厄普約翰美國公司
Publication of HK1053058A1 publication Critical patent/HK1053058A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
HK03105334.1A 2000-02-23 2003-07-24 普拉克索用於治療成癮性疾病的用途 HK1053058A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18424200P 2000-02-23 2000-02-23
PCT/US2001/001232 WO2001062249A1 (en) 2000-02-23 2001-02-14 Use of pramipexole for the treatment of addictive disorders

Publications (1)

Publication Number Publication Date
HK1053058A1 true HK1053058A1 (zh) 2003-10-10

Family

ID=22676121

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105334.1A HK1053058A1 (zh) 2000-02-23 2003-07-24 普拉克索用於治療成癮性疾病的用途

Country Status (24)

Country Link
US (1) US6410579B2 (zh)
EP (1) EP1257271B1 (zh)
JP (1) JP2003523387A (zh)
KR (1) KR20030016230A (zh)
CN (1) CN1396826A (zh)
AR (1) AR027945A1 (zh)
AT (1) ATE326967T1 (zh)
AU (1) AU781358B2 (zh)
BR (1) BR0107983A (zh)
CA (1) CA2397874A1 (zh)
CO (1) CO5261586A1 (zh)
DE (1) DE60119896T2 (zh)
DK (1) DK1257271T3 (zh)
ES (1) ES2263586T3 (zh)
HK (1) HK1053058A1 (zh)
MX (1) MXPA02008184A (zh)
MY (1) MY127739A (zh)
NZ (1) NZ520974A (zh)
PE (1) PE20011074A1 (zh)
PT (1) PT1257271E (zh)
SI (1) SI1257271T1 (zh)
TW (1) TWI250016B (zh)
WO (1) WO2001062249A1 (zh)
ZA (1) ZA200206119B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
ATE480235T1 (de) 2001-12-11 2010-09-15 Univ Virginia Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
AR040682A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
JP2007518754A (ja) * 2004-01-22 2007-07-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング モノアミン神経伝達物質再取込みインヒビターとドーパミンアゴニストを含む医薬組成物
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP4971159B2 (ja) * 2004-08-13 2012-07-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用
CN101849921A (zh) * 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
CA2641665A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
KR20090021169A (ko) 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008113056A2 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
ATE513830T1 (de) * 2007-09-21 2011-07-15 Sanofi Aventis Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP2334185A4 (en) 2008-08-19 2011-09-21 Knopp Neurosciences Inc COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
DE102012108398B4 (de) 2012-09-10 2014-05-22 Schott Ag Kochfeld, Blende, Geräteeinhausung sowie Kamin- oder Ofensichtscheibe mit einem Hologramm und Verfahren zu dessen bzw. deren Herstellung, sowie Verwendung eines Substrats, auf welchem ein Phasenhologramm aufgebracht ist
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
PL3019167T3 (pl) 2013-07-12 2021-06-14 Knopp Biosciences Llc Leczenie podwyższonych poziomów eozynofili i/lub bazofili
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
HUE055850T2 (hu) 2013-08-13 2022-01-28 Knopp Biosciences Llc Készítmények és módszerek a krónikus urticaria (csalánkiütés) kezelésére

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186087B1 (de) 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
DE3843227A1 (de) 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
DE3930282A1 (de) 1989-09-11 1991-03-21 Boehringer Ingelheim Kg Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit
DE3933738A1 (de) 1989-10-10 1991-04-11 Boehringer Ingelheim Kg Neue verwendung von 2-aminothiazol-derivaten (tsh)
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE4241013A1 (de) 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
US5650420A (en) 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6001861A (en) 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
AU7620600A (en) * 1999-09-30 2001-04-30 General Hospital Corporation, The Use of pramipexole as a treatment for cocaine craving

Also Published As

Publication number Publication date
DE60119896T2 (de) 2006-11-09
EP1257271A1 (en) 2002-11-20
AU781358B2 (en) 2005-05-19
DE60119896D1 (de) 2006-06-29
MXPA02008184A (es) 2002-11-29
EP1257271B1 (en) 2006-05-24
AR027945A1 (es) 2003-04-16
TWI250016B (en) 2006-03-01
BR0107983A (pt) 2003-01-28
ZA200206119B (en) 2003-10-31
DK1257271T3 (da) 2006-08-21
CN1396826A (zh) 2003-02-12
MY127739A (en) 2006-12-29
US20010041727A1 (en) 2001-11-15
CO5261586A1 (es) 2003-03-31
PT1257271E (pt) 2006-09-29
KR20030016230A (ko) 2003-02-26
JP2003523387A (ja) 2003-08-05
NZ520974A (en) 2004-04-30
AU3445401A (en) 2001-09-03
ATE326967T1 (de) 2006-06-15
SI1257271T1 (sl) 2006-10-31
WO2001062249A1 (en) 2001-08-30
CA2397874A1 (en) 2001-08-30
ES2263586T3 (es) 2006-12-16
US6410579B2 (en) 2002-06-25
PE20011074A1 (es) 2001-10-04

Similar Documents

Publication Publication Date Title
HK1053058A1 (zh) 普拉克索用於治療成癮性疾病的用途
GB0007193D0 (en) Treatment of movrmrnt disorders
ZA200401004B (en) Combination for the treatment of inflammatory disorders
IL153425A0 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
HUP0302719A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
IL209842A0 (en) Compounds for the treatment of metabolic disorders
EP1274444A4 (en) DRUGS FOR THE TREATMENT OF PSYCHIATRICAL OR ABUSUS-RELATED DISORDER
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
PL369763A1 (en) Heterocyclic compounds for use in the treatment of disorders of the urinary tract
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
AU2001293891A1 (en) New combination for the treatment of asthma
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HK1049122A1 (en) The use of mirtazapine for the treatment of sleep disorders
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
IL154378A0 (en) Compounds for the treatment of addictive disorders
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
PT1698338E (pt) S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
SI1200447T1 (en) Oxazinocarbazoles for the treatment of cns diseases
GB0004998D0 (en) The treatment of functional gastrointestinal disorders
GB0017951D0 (en) Treatment of movement disorders